Hematologic Oncology Update CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
Dec 11, 2025
In this insightful discussion, Dr. Jeremy S Abramson, a lymphoma specialist at Massachusetts General Hospital, and Dr. Loretta J Nastoupil from CommonSpirit Mercy Hospital explore the landscape of CAR T-cell therapy for non-Hodgkin lymphoma. They delve into patient access challenges, revealing under 20% of eligible patients reach treatment centers. The pair compare CAR T products and emphasize the importance of logistical support for patients. They also address the significance of wellness strategies and community collaboration in enhancing patient care.
AI Snips
Chapters
Transcript
Episode notes
Patient Framing: ‘Bionic’ T Cells
- A patient described CAR‑T to friends as "we made your T cells bionic" which helped others understand.
- He credited CAR‑T with saving his life and seven years of family time.
Match CAR‑T Choice To Urgency And Tolerance
- Consider product toxicity and turnaround when choosing CAR‑T; efficacy across products appears similar.
- Prefer faster products for urgent disease and lower‑toxicity products for frail patients.
Start CAR‑T Early In DLBCL Relapse
- For most relapsed DLBCL patients, initiate CAR‑T evaluation immediately after frontline failure.
- Reserve transplant for young fit late relapsers; otherwise use CAR‑T in second line.